SARTORIUS STEDIM BIOTECH (56S1.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:56S1 - FR0013154002 - Common Stock
220.9 EUR
-1.9 (-0.85%)
Taking everything into account, 56S1 scores 4 out of 10 in our fundamental rating. 56S1 was compared to 22 industry peers in the Life Sciences Tools & Services industry. 56S1 has an average financial health and profitability rating. 56S1 is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
In the past year 56S1 was profitable.
56S1 had a positive operating cash flow in the past year.
Each year in the past 5 years 56S1 has been profitable.
56S1 had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
With a Return On Assets value of 3.35%, 56S1 is not doing good in the industry: 63.64% of the companies in the same industry are doing better.
56S1 has a Return On Equity of 6.54%. This is comparable to the rest of the industry: 56S1 outperforms 40.91% of its industry peers.
56S1 has a Return On Invested Capital of 5.94%. This is comparable to the rest of the industry: 56S1 outperforms 50.00% of its industry peers.
56S1 had an Average Return On Invested Capital over the past 3 years of 10.41%. This is in line with the industry average of 9.70%.
The last Return On Invested Capital (5.94%) for 56S1 is well below the 3 year average (10.41%), which needs to be investigated, but indicates that 56S1 had better years and this may not be a problem.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.35% | ||
| ROE | 6.54% | ||
| ROIC | 5.94% |
ROA(3y)7.81%
ROA(5y)9.13%
ROE(3y)17.3%
ROE(5y)20.06%
ROIC(3y)10.41%
ROIC(5y)14.57%
1.3 Margins
56S1 has a Profit Margin (8.96%) which is in line with its industry peers.
56S1's Profit Margin has declined in the last couple of years.
56S1 has a better Operating Margin (16.63%) than 63.64% of its industry peers.
In the last couple of years the Operating Margin of 56S1 has declined.
56S1 has a Gross Margin (45.64%) which is in line with its industry peers.
56S1's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 16.63% | ||
| PM (TTM) | 8.96% | ||
| GM | 45.64% |
OM growth 3Y-22.38%
OM growth 5Y-9.98%
PM growth 3Y-24.01%
PM growth 5Y-17.3%
GM growth 3Y-6.9%
GM growth 5Y-3.53%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), 56S1 is creating some value.
Compared to 1 year ago, 56S1 has more shares outstanding
Compared to 5 years ago, 56S1 has more shares outstanding
56S1 has a better debt/assets ratio than last year.
2.2 Solvency
56S1 has an Altman-Z score of 4.66. This indicates that 56S1 is financially healthy and has little risk of bankruptcy at the moment.
With a decent Altman-Z score value of 4.66, 56S1 is doing good in the industry, outperforming 77.27% of the companies in the same industry.
The Debt to FCF ratio of 56S1 is 6.84, which is on the high side as it means it would take 56S1, 6.84 years of fcf income to pay off all of its debts.
56S1's Debt to FCF ratio of 6.84 is in line compared to the rest of the industry. 56S1 outperforms 45.45% of its industry peers.
56S1 has a Debt/Equity ratio of 0.50. This is a healthy value indicating a solid balance between debt and equity.
56S1 has a Debt to Equity ratio (0.50) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 6.84 | ||
| Altman-Z | 4.66 |
ROIC/WACC0.63
WACC9.4%
2.3 Liquidity
56S1 has a Current Ratio of 1.05. This is a normal value and indicates that 56S1 is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of 56S1 (1.05) is worse than 72.73% of its industry peers.
56S1 has a Quick Ratio of 1.05. This is a bad value and indicates that 56S1 is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.50, 56S1 is doing worse than 81.82% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.05 | ||
| Quick Ratio | 0.5 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 35.11% over the past year.
The Earnings Per Share has been growing slightly by 4.19% on average over the past years.
The Revenue has been growing slightly by 7.72% in the past year.
The Revenue has been growing by 14.05% on average over the past years. This is quite good.
EPS 1Y (TTM)35.11%
EPS 3Y-22.3%
EPS 5Y4.19%
EPS Q2Q%23.68%
Revenue 1Y (TTM)7.72%
Revenue growth 3Y-1.25%
Revenue growth 5Y14.05%
Sales Q2Q%7.67%
3.2 Future
56S1 is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.11% yearly.
56S1 is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.12% yearly.
EPS Next Y29.39%
EPS Next 2Y23.86%
EPS Next 3Y23.06%
EPS Next 5Y22.11%
Revenue Next Year7.45%
Revenue Next 2Y8.04%
Revenue Next 3Y9.07%
Revenue Next 5Y10.12%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 51.25 indicates a quite expensive valuation of 56S1.
Based on the Price/Earnings ratio, 56S1 is valued a bit more expensive than 77.27% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 27.00. 56S1 is valued rather expensively when compared to this.
56S1 is valuated quite expensively with a Price/Forward Earnings ratio of 41.14.
56S1's Price/Forward Earnings ratio is a bit more expensive when compared to the industry. 56S1 is more expensive than 72.73% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 23.70. 56S1 is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 51.25 | ||
| Fwd PE | 41.14 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, 56S1 is valued a bit more expensive than the industry average as 77.27% of the companies are valued more cheaply.
56S1's Price/Free Cash Flow ratio is in line with the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 57.41 | ||
| EV/EBITDA | 29.43 |
4.3 Compensation for Growth
56S1's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
56S1's earnings are expected to grow with 23.06% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.74
PEG (5Y)12.22
EPS Next 2Y23.86%
EPS Next 3Y23.06%
5. Dividend
5.1 Amount
56S1 has a yearly dividend return of 0.33%, which is pretty low.
Compared to an average industry Dividend Yield of 0.48, 56S1 has a dividend in line with its industry peers.
With a Dividend Yield of 0.33, 56S1 pays less dividend than the S&P500 average, which is at 1.94.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.33% |
5.2 History
The dividend of 56S1 has a limited annual growth rate of 4.44%.
Dividend Growth(5Y)4.44%
Div Incr Years0
Div Non Decr Years1
5.3 Sustainability
56S1 pays out 25.41% of its income as dividend. This is a sustainable payout ratio.
56S1's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP25.41%
EPS Next 2Y23.86%
EPS Next 3Y23.06%
FRA:56S1 (1/8/2026, 7:00:00 PM)
220.9
-1.9 (-0.85%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners11.88%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap21.50B
Revenue(TTM)2.95B
Net Income(TTM)264.10M
Analysts81.11
Price Target240.69 (8.96%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.33% |
Yearly Dividend0.71
Dividend Growth(5Y)4.44%
DP25.41%
Div Incr Years0
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.99%
Min EPS beat(2)-2.24%
Max EPS beat(2)10.22%
EPS beat(4)3
Avg EPS beat(4)9.45%
Min EPS beat(4)-2.24%
Max EPS beat(4)22.18%
EPS beat(8)3
Avg EPS beat(8)-1.58%
EPS beat(12)3
Avg EPS beat(12)-11.08%
EPS beat(16)4
Avg EPS beat(16)-13.1%
Revenue beat(2)1
Avg Revenue beat(2)-1.82%
Min Revenue beat(2)-3.94%
Max Revenue beat(2)0.3%
Revenue beat(4)3
Avg Revenue beat(4)0.7%
Min Revenue beat(4)-3.94%
Max Revenue beat(4)3.52%
Revenue beat(8)5
Avg Revenue beat(8)-0.23%
Revenue beat(12)5
Avg Revenue beat(12)-1.54%
Revenue beat(16)7
Avg Revenue beat(16)-0.72%
PT rev (1m)0.77%
PT rev (3m)0.51%
EPS NQ rev (1m)4.24%
EPS NQ rev (3m)14.4%
EPS NY rev (1m)-0.01%
EPS NY rev (3m)1.39%
Revenue NQ rev (1m)-0.08%
Revenue NQ rev (3m)0.03%
Revenue NY rev (1m)-1.45%
Revenue NY rev (3m)-1.45%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 51.25 | ||
| Fwd PE | 41.14 | ||
| P/S | 7.3 | ||
| P/FCF | 57.41 | ||
| P/OCF | 29.43 | ||
| P/B | 5.33 | ||
| P/tB | N/A | ||
| EV/EBITDA | 29.43 |
EPS(TTM)4.31
EY1.95%
EPS(NY)5.37
Fwd EY2.43%
FCF(TTM)3.85
FCFY1.74%
OCF(TTM)7.51
OCFY3.4%
SpS30.27
BVpS41.47
TBVpS-4.02
PEG (NY)1.74
PEG (5Y)12.22
Graham Number63.42
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.35% | ||
| ROE | 6.54% | ||
| ROCE | 7.46% | ||
| ROIC | 5.94% | ||
| ROICexc | 6.26% | ||
| ROICexgc | 21.64% | ||
| OM | 16.63% | ||
| PM (TTM) | 8.96% | ||
| GM | 45.64% | ||
| FCFM | 12.71% |
ROA(3y)7.81%
ROA(5y)9.13%
ROE(3y)17.3%
ROE(5y)20.06%
ROIC(3y)10.41%
ROIC(5y)14.57%
ROICexc(3y)10.84%
ROICexc(5y)15.37%
ROICexgc(3y)26.31%
ROICexgc(5y)36.49%
ROCE(3y)13.07%
ROCE(5y)18.3%
ROICexgc growth 3Y-36.77%
ROICexgc growth 5Y-16.49%
ROICexc growth 3Y-43.34%
ROICexc growth 5Y-25.09%
OM growth 3Y-22.38%
OM growth 5Y-9.98%
PM growth 3Y-24.01%
PM growth 5Y-17.3%
GM growth 3Y-6.9%
GM growth 5Y-3.53%
F-Score8
Asset Turnover0.37
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 6.84 | ||
| Debt/EBITDA | 2.5 | ||
| Cap/Depr | 113.12% | ||
| Cap/Sales | 12.09% | ||
| Interest Coverage | 3.09 | ||
| Cash Conversion | 90.78% | ||
| Profit Quality | 141.8% | ||
| Current Ratio | 1.05 | ||
| Quick Ratio | 0.5 | ||
| Altman-Z | 4.66 |
F-Score8
WACC9.4%
ROIC/WACC0.63
Cap/Depr(3y)182.98%
Cap/Depr(5y)186.68%
Cap/Sales(3y)13.87%
Cap/Sales(5y)12.23%
Profit Quality(3y)126.76%
Profit Quality(5y)109.63%
High Growth Momentum
Growth
EPS 1Y (TTM)35.11%
EPS 3Y-22.3%
EPS 5Y4.19%
EPS Q2Q%23.68%
EPS Next Y29.39%
EPS Next 2Y23.86%
EPS Next 3Y23.06%
EPS Next 5Y22.11%
Revenue 1Y (TTM)7.72%
Revenue growth 3Y-1.25%
Revenue growth 5Y14.05%
Sales Q2Q%7.67%
Revenue Next Year7.45%
Revenue Next 2Y8.04%
Revenue Next 3Y9.07%
Revenue Next 5Y10.12%
EBIT growth 1Y25.54%
EBIT growth 3Y-23.35%
EBIT growth 5Y2.67%
EBIT Next Year93.64%
EBIT Next 3Y36.06%
EBIT Next 5Y27.7%
FCF growth 1Y219.27%
FCF growth 3Y7.94%
FCF growth 5Y22.24%
OCF growth 1Y15.97%
OCF growth 3Y5.11%
OCF growth 5Y21.32%
SARTORIUS STEDIM BIOTECH / 56S1.DE FAQ
What is the ChartMill fundamental rating of SARTORIUS STEDIM BIOTECH (56S1.DE) stock?
ChartMill assigns a fundamental rating of 5 / 10 to 56S1.DE.
Can you provide the valuation status for SARTORIUS STEDIM BIOTECH?
ChartMill assigns a valuation rating of 1 / 10 to SARTORIUS STEDIM BIOTECH (56S1.DE). This can be considered as Overvalued.
How profitable is SARTORIUS STEDIM BIOTECH (56S1.DE) stock?
SARTORIUS STEDIM BIOTECH (56S1.DE) has a profitability rating of 5 / 10.
Can you provide the PE and PB ratios for 56S1 stock?
The Price/Earnings (PE) ratio for SARTORIUS STEDIM BIOTECH (56S1.DE) is 51.25 and the Price/Book (PB) ratio is 5.33.
What is the earnings growth outlook for SARTORIUS STEDIM BIOTECH?
The Earnings per Share (EPS) of SARTORIUS STEDIM BIOTECH (56S1.DE) is expected to grow by 29.39% in the next year.